Bevacizumab in pediatric patients: How safe is it?

Anticancer Research

Volumn 31, Issue 11, 2011, Pages 3953-3957

  De Pasquale, Maria Debora ^a   Castellano, Aurora ^a   De Sio, Luigi ^a   De Laurentis, Clementina ^a   Mastronuzzi, Angela ^a   Serra, Annalisa ^a   Cozza, Raffaele ^a   Jenkner, Alessandro ^a   De Ioris, Maria Antonietta ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Bevacizumab; Pediatrics; Safety; VEGF

Indexed keywords

AMLODIPINE BESYLATE; BEVACIZUMAB; BUSULFAN; CARBOPLATIN; CARVEDILOL; CISPLATIN; CYCLOPHOSPHAMIDE; DIAZEPAM; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; LABETALOL; LEVOTHYROXINE; MELPHALAN; MYCOPHENOLIC ACID; OXALIPLATIN; PEGINTERFERON ALPHA2B; PEMETREXED; PHENOBARBITAL; RAMIPRIL; SUNITINIB; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; UNINDEXED DRUG; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CHILD; CLINICAL ARTICLE; DESMOPLASTIC SMALL ROUND CELL TUMOR; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ENTEROCUTANEOUS FISTULA; EPISTAXIS; EVALUATION; FEMALE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LYMPHOCYTOPENIA; MALE; MESOTHELIOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTIC SYNDROME; NEUROBLASTOMA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RHABDOMYOSARCOMA; SCHOOL CHILD; SEIZURE; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT WITHDRAWAL; WOUND DEHISCENCE;

ABDOMINAL NEOPLASMS; ADOLESCENT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE NEOPLASMS; CARCINOMA, EMBRYONAL; CARCINOMA, HEPATOCELLULAR; CARCINOMA, RENAL CELL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; KIDNEY NEOPLASMS; LIVER NEOPLASMS; MALE; NEOPLASMS; NEUROBLASTOMA; PROGNOSIS; RHABDOMYOSARCOMA; SARCOMA, EWING;

EID: 83055162488     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985, 1983.
2. Ferrara N: Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 280: C1358-1366, 2001.
3. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362: 841-844, 1993. (Pubitemid 23132159)
4. Glade-Bender J, Kandel JJ and Yamashiro DJ: VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther 3: 263-276, 2003. (Pubitemid 36458758)
5. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF and Kabbinavar F: Bevacizumab in combination with fluoruracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23: 3502-3508, 2005.
6. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX and Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. New Engl J Med 349(5): 427-434, 2003. (Pubitemid 36910021)
7. Welch S, Spithoff K, Rumble RB and Maroun J: Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol 25: 1-11, 2009.
8. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M and Cloughesy T: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4733-4740, 2009.
9. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Kaseb A, Glover K, Davila M and Abbruzzese J: Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27: 843-863, 2009.
10. Perez EA, Hillman DW, Dentchev T, Le-Lindqwister NA, Geeraerts LH, Fitch TR, Liu H, Graham DL, Kahanic SP, Gross HM, Patel TA, Palmieri FM and Dueck AC: North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Ann Oncol 21: 269-274, 2010.
11. Pavlakovic H, Von Schütz V, Rössler J, Koscielniak E, Havers W and Schweigerer L: Quantification of angiogenesis stimulators in children with solid malignancies. Int J Cancer 92: 756-760, 2001. (Pubitemid 32385721)
12. Rowe DH, Huang J, Kayton ML et al.: Anti- VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg 35: 30-33, 2000. (Pubitemid 30062829)
13. Rowe DH, Huang J, Li J et al.: Suppression of primary tumor growth in a mouse model of human neuroblastoma. J Pediatr Surg 35: 977-981, 2000. (Pubitemid 30346200)
14. McCrudden KW, Hopkins B, Frischer J et al.: Anti-VEGF antibody in experimental hepatoblastoma: Suppression of tumor growth and altered angiogenesis. J Pediatr Surg 38: 308-314, 2003. (Pubitemid 36278684)
15. Gerber HP, Kowalski J, Sherman D et al.: Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 60: 6253-6258, 2000.
16. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference- 5x7.pdf
17. Glade Bender JL, Adamson PC, Reid JM et al.: Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a children's oncology group study. J Clin Oncol 26: 399-405, 2008. (Pubitemid 351171691)
18. Benesch M, Windelberg M, Sauseng W et al.: Compassionate use of bevacizumab (Avastin®) in children and young adults with refractory or recurrent solid tumors. Ann Oncol 19: 807-813, 2008. (Pubitemid 351461055)
19. Reismuller B, Azizi AA, Peryl A et al.: Feasibility and tolerability of bevacizumab in children with primary CNS tumor. Pediatr Blood Cancer 54: 681-686, 2010.
20. Gugurangan S, Chi SN, Young T et al.: Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a pediatric brain tumor consortium study. J Clin Oncol 28: 3069-3075, 2010.
21. Shord SS, Bressler LR, Tierney LA et al.: Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health-Syst Pharm 66: 999-1013, 2009.
22. Glusker P, Recht L and Lane B: Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354: 980-982, 2006.
23. Allen JA, Adlakha A and Bergeton PR: Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 63: 1475-1478, 2006. (Pubitemid 44547561)
24. Ozcan C, Wong SJ and Hari P: Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354: 980-982, 2006.
25. Levy CF, Oo KZ, Fireman F et al.: Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab. Pediatr Blood Cancer 52: 669-671, 2009.
26. BC Cancer Agency. Management guidelines for bevacizumab related side effect in patients with colorectal cancer. http://www.bccancer.bc.ca/NR/ rdonlyres/52C02943-7379-4B24BC9D-A20AF1A3A1D2/51873/bevacizumab-monograph- 1July2011.pdf
27. Przybylski M: A review of the current research on the role of bFGF and VEGF in angiogenesis. J Wound Care 18: 516-519, 2009.